Cencora, Inc. $COR Stock Position Lowered by Great Lakes Advisors LLC

Great Lakes Advisors LLC lowered its position in shares of Cencora, Inc. (NYSE:COR) by 20.8% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 342,407 shares of the company’s stock after selling 90,082 shares during the period. Great Lakes Advisors LLC’s holdings in Cencora were worth $107,014,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the company. Cornerstone Wealth Group LLC lifted its holdings in Cencora by 1.3% in the 3rd quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company’s stock valued at $745,000 after acquiring an additional 30 shares during the last quarter. Security Financial Services INC. lifted its stake in Cencora by 2.6% during the third quarter. Security Financial Services INC. now owns 1,325 shares of the company’s stock valued at $414,000 after purchasing an additional 33 shares during the last quarter. Atlantic Edge Private Wealth Management LLC lifted its stake in Cencora by 70.0% during the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after purchasing an additional 35 shares during the last quarter. Hemington Wealth Management boosted its holdings in Cencora by 12.0% during the third quarter. Hemington Wealth Management now owns 327 shares of the company’s stock worth $102,000 after buying an additional 35 shares in the last quarter. Finally, Quadcap Wealth Management LLC grew its position in Cencora by 1.5% in the second quarter. Quadcap Wealth Management LLC now owns 2,409 shares of the company’s stock worth $722,000 after buying an additional 36 shares during the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Stock Performance

Shares of Cencora stock opened at $350.13 on Thursday. Cencora, Inc. has a 12 month low of $237.71 and a 12 month high of $377.54. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32. The stock has a market cap of $67.92 billion, a PE ratio of 44.04, a price-to-earnings-growth ratio of 1.69 and a beta of 0.66. The business has a fifty day simple moving average of $347.96 and a 200-day simple moving average of $323.25.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The firm had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. During the same period in the prior year, the business earned $3.34 EPS. The business’s revenue for the quarter was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, sell-side analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. This is a positive change from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend was Friday, November 14th. Cencora’s payout ratio is currently 30.19%.

Insider Buying and Selling

In related news, EVP Elizabeth S. Campbell sold 3,351 shares of the business’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the transaction, the executive vice president directly owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. The trade was a 12.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Silvana Battaglia sold 1,677 shares of the stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the completion of the sale, the executive vice president owned 18,796 shares of the company’s stock, valued at approximately $6,484,620. The trade was a 8.19% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 20,316 shares of company stock worth $7,151,265. 0.38% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on COR shares. Wells Fargo & Company increased their price objective on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. Evercore ISI set a $400.00 target price on Cencora and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Barclays started coverage on Cencora in a report on Monday, December 8th. They set an “overweight” rating and a $400.00 target price for the company. Wall Street Zen cut Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. Finally, UBS Group boosted their price objective on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a report on Friday, November 7th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $393.08.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.